Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q4 Earnings Snapshot

Marinus Pharmaceuticals: Q4 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q3 Earnings Snapshot

Marinus Pharmaceuticals: Q3 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q2 Earnings Snapshot

Marinus Pharmaceuticals: Q2 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals: Q1 Earnings Snapshot

Marinus Pharmaceuticals: Q1 Earnings Snapshot

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present...

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial...

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H....

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards...

MRNS : 1.4300 (+1.06%)
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration...

MRNS : 1.4300 (+1.06%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain'
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar